KR930700106A - 혈전증 치료제 및 포스포 디에스테라제 저해제 - Google Patents

혈전증 치료제 및 포스포 디에스테라제 저해제

Info

Publication number
KR930700106A
KR930700106A KR1019920703088A KR920703088A KR930700106A KR 930700106 A KR930700106 A KR 930700106A KR 1019920703088 A KR1019920703088 A KR 1019920703088A KR 920703088 A KR920703088 A KR 920703088A KR 930700106 A KR930700106 A KR 930700106A
Authority
KR
South Korea
Prior art keywords
carbostyryl
amino
derivative
hydroxy propoxy
carbostyryl derivative
Prior art date
Application number
KR1019920703088A
Other languages
English (en)
Inventor
다까후미 후지오까
슈지 데라모또
미찌아끼 도미나가
요이지 야부우찌
Original Assignee
오스카 아끼히꼬
오스카 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오스카 아끼히꼬, 오스카 세이야꾸 가부시끼가이샤 filed Critical 오스카 아끼히꼬
Publication of KR930700106A publication Critical patent/KR930700106A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

내용 없음.

Description

혈전증 치료제 및 포스포 디에스테라제 저해제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 일반식
    [식중, R1은 수소원자 또는 치환기로서 수산기를 갖을수 있는 저급 알킬기를 나타낸다. R2는 페닐고리상에 치환기로서 저급 알콕시기 및 할로겐 원자로된 군에서 선택된 기를 1-3개 갖을수 있는 페닐 저급 알킬기, 피리딜 저급 알킬기 또는 -A-NR3R4(여기서, A는 저급알킬렌기, R3및 R4는 동일하거나 다를수 있으며 각각 저급알킬기 또는 페닐기임)을 나타낸다.]로 표시되는 카르보스티릴 유도체 및 그 염으로된 군에서 선택된 적어도 1종을 함유하는 혈전증 치료제.
  2. 제1항에 있어서의 카르보스티릴 유도체 및 그 염의 적어도 1종을 함유하는 혈소판 응집억제제.
  3. 제1항에 있어서의 카르보스티릴 유도체 및 그 염의 적어도 1종을 함유하는 포스포 디에스테라제 저해제.
  4. 제1항에 있어서의 카르보스티릴 유도체 및 그 염의 적어도 1종을 함유하는 뇌순환 개선제.
  5. 제1항에 있어서의 카르보스티릴 유도체 및 그 염의 적어도 1종을 함유하는 혈소판 덩어리 해리제.
  6. 제1항에 있어서, 카르보스티릴 유도체가 6-[3-(3-메톡시벤질)아미노-2-히드록시 프로폭시]카르보 스티릴인 혈전증 치료제.
  7. 제1항에 있어서, 카르보스티릴 유도체가 6-[3-(3,4-디메톡시 벤질)아미노-2-히드록시 프로폭시]카르보스티릴인 혈전증 치료제.
  8. 제3항에 있어서, 카르보스티릴 유도체가 6-[3(3-메톡시벤질)아미노-2-히드록시 프로폭시]카르보스티릴인 포스포 디에스테라제 저해제.
  9. 제3항에 있어서, 카르보스티릴 유도체가 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시 프로폭시]카르보스티릴인 포스포 디에스테라제 저해제.
  10. 제2항에 있어서, 카르보스티릴 유도체가 6-[3-(3-메톡시벤질)아미노-2-히드록시 프로폭시]카르보티릴인 혈소판 응집억제제.
  11. 제2항에 있어서, 카르보스티릴 유도체가 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시 프로폭시]카르보스티릴인 혈소판 응집억제제.
  12. 제4항에 있어서, 카르보스티릴 유도체가 6-[3-(3-메톡시벤질)아미노-2-히드록시 프로폭시]카르보티릴인 뇌순환 개선제.
  13. 제4항에 있어서, 카르보스티릴 유도체가 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시 프로폭시]카르보스티릴인 뇌순환 개선제.
  14. 제5항에 있어서, 카르보스티릴 유도체가 6-[3-(3-메톡시벤질)아미노-2-히드록시 프로폭시]카르보스티릴인 혈소판 덩어리 해리제.
  15. 제5항에 있어서, 카르보스티릴 유도체가 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시 프로폭시]카르보스티릴인 혈소판 덩어리 해리제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019920703088A 1991-04-03 1992-03-26 혈전증 치료제 및 포스포 디에스테라제 저해제 KR930700106A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP7022391 1991-04-03
JP91-70223 1991-04-03
JP92-21137 1992-02-06
JP2113792 1992-02-06
PCT/JP1992/000368 WO1992017178A1 (en) 1991-04-03 1992-03-26 Remedy for thrombosis and phosphodiesterase inhibitor

Publications (1)

Publication Number Publication Date
KR930700106A true KR930700106A (ko) 1993-03-13

Family

ID=26358162

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920703088A KR930700106A (ko) 1991-04-03 1992-03-26 혈전증 치료제 및 포스포 디에스테라제 저해제

Country Status (8)

Country Link
US (2) US5401754A (ko)
EP (2) EP0531548B1 (ko)
JP (1) JPH05279256A (ko)
KR (1) KR930700106A (ko)
DE (2) DE69205106T2 (ko)
DK (1) DK0531548T3 (ko)
TW (1) TW201305B (ko)
WO (1) WO1992017178A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2121148A1 (en) * 1992-08-19 1994-03-03 Satoru Nakai Apoptosis regulator
US5654317A (en) * 1992-09-18 1997-08-05 Otsuka Pharmaceutical Company, Limited Antiarrhythmic agent
KR19980701286A (ko) * 1995-01-09 1998-05-15 오스카 아키히코 Tnf-알파 억제제
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US5958982A (en) * 1998-04-17 1999-09-28 Cell Pathways, Inc. Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols
US5902827A (en) * 1998-04-17 1999-05-11 Cell Pathways Method for treating patients with psoriasis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols
US6025394A (en) * 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6531603B1 (en) 2001-06-29 2003-03-11 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6388080B1 (en) 2001-06-29 2002-05-14 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6660864B2 (en) 2001-06-29 2003-12-09 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6573382B2 (en) 2001-06-29 2003-06-03 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6657061B2 (en) 2001-06-29 2003-12-02 Grayson Walker Stowell Polymorphic forms of 6-[4-1(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6596871B2 (en) 2001-06-29 2003-07-22 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
TW200402402A (en) * 2002-06-05 2004-02-16 Komuro Toshio Antithrombogenic platiniferous ceramic composition and article containing the same
JP2006513222A (ja) * 2002-12-23 2006-04-20 アルテシアン セラピューティック，インコーポレイティド アドレナリン性β受容体およびホスホジエステラーゼに対する抑制活性を有する強心性化合物
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
WO2005009446A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050130971A1 (en) * 2003-08-22 2005-06-16 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
JP2010514841A (ja) * 2007-01-03 2010-05-06 グレン ブイ． コルネット， 肺疾患および心疾患の処置におけるシクレタニンおよびｐｋｃ阻害剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4951271A (ko) * 1972-09-28 1974-05-18
JPS5082218A (ko) * 1973-11-10 1975-07-03
JPS5310989B2 (ko) * 1974-04-25 1978-04-18
JPS5936617B2 (ja) * 1976-03-05 1984-09-05 大塚製薬株式会社 カルボスチリル誘導体
JPS6059912B2 (ja) * 1978-02-28 1985-12-27 大塚製薬株式会社 カルボスチリル誘導体
IE46852B1 (en) * 1977-06-10 1983-10-05 Otsuka Pharma Co Ltd Novel carbostyril derivatives
JPS5430184A (en) * 1977-08-10 1979-03-06 Otsuka Pharmaceut Co Ltd 3,4-dihydrocarbostyril derivative
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DK36980A (da) * 1979-01-30 1980-07-31 Otsuka Pharma Co Ltd Fremgangsmaade til bestemmelse af tumorforbundet glycobindingsholdigt stof og diagnosticering af cancer
JPS55129268A (en) * 1979-03-28 1980-10-06 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS568319A (en) * 1980-03-26 1981-01-28 Otsuka Pharmaceut Co Ltd Antihistamine
JPS572274A (en) * 1980-06-06 1982-01-07 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5714574A (en) * 1980-06-27 1982-01-25 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5780322A (en) * 1980-11-05 1982-05-19 Otsuka Pharmaceut Co Ltd Cardiotonic agent
JPS5793962A (en) * 1980-12-01 1982-06-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0355583B1 (en) * 1988-08-10 1995-01-25 Otsuka Pharmaceutical Co., Ltd. Cardiotonics

Also Published As

Publication number Publication date
TW201305B (ko) 1993-03-01
DE69205106D1 (de) 1995-11-02
US5401754A (en) 1995-03-28
DE69233356D1 (de) 2004-07-01
EP0647447B1 (en) 2004-05-26
WO1992017178A1 (en) 1992-10-15
JPH05279256A (ja) 1993-10-26
EP0647447A1 (en) 1995-04-12
EP0531548A1 (en) 1993-03-17
US5532253A (en) 1996-07-02
EP0531548B1 (en) 1995-09-27
EP0531548A4 (en) 1993-12-08
DK0531548T3 (da) 1995-11-27
DE69205106T2 (de) 1996-02-29

Similar Documents

Publication Publication Date Title
KR930700106A (ko) 혈전증 치료제 및 포스포 디에스테라제 저해제
MA18694A1 (fr) Nouveaux derives de piperidinyl alkyl-quinazoline
YU47114B (sh) Metalno kompleksno jedinjenje postupak za dobijanje i postupak za korišćenje
MY111683A (en) Indole derivatives.
BG100154A (en) Carbazole derivatibes having inhibiting effect to 17,20-lyase
ES8506629A1 (es) Un procedimiento para preparar derivados de piridina
KR960007565A (ko) 약제로서의 치환된 4-페닐-6-아미노-니코틴산 유도체의 용도
KR960022486A (ko) 신규 티아졸리딘-4-온 유도체
ATE59632T1 (de) Dihydrodibenzocycloheptylidenethylamin-derivate
ES2019163A6 (es) Procedimiento para preparar derivados de imidazol.
KR890012989A (ko) 아크릴산 모르폴리드, 그의 제조방법 및 용도
KR920004340A (ko) 술폰아미드 유도체
IE830976L (en) 3-(arylthiomethyl)pyridines.
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
YU140391A (sh) 6-supstituisani-heksahidrobenz (cd)-indoli
GB1169945A (en) Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
KR900003122A (ko) 카테콜 유도체
KR930021629A (ko) 피페라진 유도체
DK440183D0 (da) Ethanderivater med fungicid virkning
ES8704478A1 (es) Procedimiento para la obtencion de derivados de piridina
ES2043820T3 (es) Nuevas 1-1 alkil-1-sulfonil-2-alkoxicarbonilsulfenilhidrazinas que tienen actividad antineoplastica.
KR950704252A (ko) N-치환 이미다졸 유도체
EP0294937A3 (en) Novel cinnamoylamide derivatives
TW333525B (en) New perhydroisoindole derivatives, their preparation and the pharmaceutical compositions which contain them the invention relates to perhydroisoindole derivatives of general formula (I), and their salts when they exist advantageously as neurokinin A antagonists.
DK293885D0 (da) Aroylsubstituerede dihydro-1,4-thiaziner og salte deraf samt deres fremstilling og anvendelse

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
E601 Decision to refuse application